Barzolvolimab improved symptoms in chronic spontaneous urticaria, supporting mast cell targeting as a novel treatment strategy. Read more.
In this exclusive MedPage Today video, Jonathan Bernstein, MD, of the University of Cincinnati College of Medicine, discusses emerging data on barzolvolimab, an investigational humanized monoclonal ...
Depending on one's perspective, "mast cell activation syndrome (MCAS)" is either a relatively rare, narrowly defined severe allergic condition or a vastly under-recognized underlying cause of multiple ...
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses ...
According to an international multicenter study, CD2-negative mast cells are associated with significantly reduced overall survival in patients with SM. Patients with CD2-negative mast cells have ...
Hosted on MSN
Allergic to Everything - The Mysteries of Mast Cells
In early 2020, Wynde Dyer walked into the house that would transform her life. The Central California ranch sat on a cul-de-sac of gated homes and glittering aquamarine pools. It boasted private ...
In 2015, Marla Barkoff, MD, was a healthy mom and board-certified endocrinologist practicing at the University of Illinois Hospital in Chicago when a bunch of debilitating symptoms landed her on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results